Sanofi's Dupixent To Keep Soaring Despite NICE Blip
HTA Body Rejects Blockbuster For Severe Asthma
Executive Summary
NICE is not recommending Dupixent for severe asthma just yet but Sanofi remains confident of hitting its sales target of €10bn a year.
You may also be interested in...
Real-World Evidence: Sanofi Push Driven By Aetion Deal
Sanofi and US start-up Aetion are to collaborate on integrating their real-world evidence and analytics platforms to improve the clinical development process.
Sanofi Skates To Where The Puck Is With Immunology
The French drugmaker has not abandoned oncology but has made it very clear that immunology and inflammation is the priority for its R&D euros.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.